Home » Jazz Pharmaceuticals Submits NDA for JZP-6 for Fibromyalgia
Jazz Pharmaceuticals Submits NDA for JZP-6 for Fibromyalgia
Jazz Pharmaceuticals, Inc. announced it has submitted a New Drug Application
(NDA) to the U.S. Food and Drug Administration for JZP-6 (sodium oxybate oral solution) for the treatment of fibromyalgia.
Fox Business
Fox Business
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May